Using mass spectrometry to monitor multiple myeloma
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
This study is testing a new way to use mass spectrometry to see if it can help doctors better detect and monitor multiple myeloma in patients by analyzing their blood samples.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Zhujiang Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05686447 on ClinicalTrials.gov |
What this trial studies
This study aims to utilize MALDI-TOF mass spectrometry to detect, characterize, and quantify M-protein in patients with multiple myeloma. By analyzing serum samples, the study seeks to provide a more precise diagnostic tool and monitor treatment responses in a sensitive and specific manner. The approach focuses on improving early diagnosis and risk assessment of multiple myeloma, which currently lacks effective large-scale screening methods. The study will include both diagnosed patients and healthy controls for comparison.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with multiple myeloma who have serum samples available for analysis.
Not a fit: Patients with incomplete sample information or those whose samples do not meet collection and storage requirements may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could lead to earlier diagnosis and better monitoring of treatment responses in multiple myeloma patients.
How similar studies have performed: Other studies have shown promise in using mass spectrometry for protein analysis, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:(1) Inclusion criteria for cases: Serum samples from related people diagnosed with multiple myeloma were included in MALDI-TOF-MS analysis by serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (IFE), Ig isotype detection and other methods. (2) Inclusion criteria of the controls were as follows: individuals in good health without obvious disease and with normal physical examination report; Avoid people who have not suffered from major chronic diseases in recent years, such as hypertension, diabetes, chronic kidney disease, etc; controls were appropriately selected that matched cases for age and sex. \- Exclusion Criteria: samples with incomplete sample information and untraceable source; Samples whose sample volume is insufficient for testing; Samples that do not meet the requirements for sample collection and storage \-
Where this trial is running
Guangzhou, Guangdong
- Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Nianyi Zeng
- Email: zengny1@i.smu.edu.cn
- Phone: 13928801657
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.